Chronology and complexities of ovarian tumorigenesis in FORKO mice: Age-dependent gene alterations and progressive dysregulation of Major Histocompatibility Complex (MHC) Class I and II profiles

Molecular and Cellular Endocrinology

Volumn 329, Issue 1-2, 2010, Pages 37-46

  Aravindakshan, J ^a   Chen, X L ^a   Sairam, M R ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Aging; FORKO; Microarray; Ovary; Tumors

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANGIOPOIETIN 2; ANGIOTENSIN 2 RECEPTOR; BETA 2 MICROGLOBULIN; CATHEPSIN E; CD4 ANTIGEN; CD74 ANTIGEN; CD8 ANTIGEN; CD8ALPHA ANTIGEN; CD8BETA ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; FIBRONECTIN; FOLLITROPIN RECEPTOR; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NERVE CELL ADHESION MOLECULE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1;

CARCINOGENESIS; DOWN REGULATION; EPITHELIUM; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; IMMUNOSURVEILLANCE; MOUSE STRAIN; NONHUMAN; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; UPREGULATION;

AGE FACTORS; ANIMALS; FEMALE; FOLLICLE STIMULATING HORMONE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; MICE; MICE, KNOCKOUT; OVARIAN NEOPLASMS; TUMOR ESCAPE;

EID: 77957117208     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.05.015     Document Type: Review

References (36)

1. Abel M.H., Huhtaniemi I., Pakarinen P., Kumar T.R., Charlton H.M. Age-related uterine and ovarian hypertrophy in FSH receptor knockout and FSHbeta subunit knockout mice. Reproduction 2003, 125:165-173.
2. Aravindakshan J., Chen X.L., Sairam M.R. Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants. Neoplasia 2006, 8:984-994.
3. Aravindakshan J., Chen X., Sairam M.R. Age dependent bimodal GDNF regulation during ovarian tumorigenesis in Follitropin receptor mutant mice. Biochem. Biophys. Res. Commun. 2006, 351:507-513.
4. Barnett J.C., Bean S.M., Whitaker R.S., Kondoh E., Baba T., Fujii S., Marks J.R., Dressman H.K., Murphy S.K., Berchuck A. Ovarian cancer tumor infiltrating T-regulatory T(reg) cells are associated with a metastatic phenotype. Gynecol. Oncol. 2010, 116:556-562.
5. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9:415-428.
6. Capo-chichi C.D., Roland I.H., Vanderveer L., Bao R., Yamagata T., Hirai H., Cohen C., Hamilton T.C., Godwin A.K., Xu X.X. Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res. 2003, 63:4967-4977.
7. Chen X.L., Aravindakshan J., Yang Y., Sairam M.R. Alterations in ovarian surface epithelium and age dependent propensity for ovarian tumors in FSH receptor knockout (FORKO) female mice. Fertil. Steril. 2005, 84:S61.
8. Chen X.L., Aravindakshan J., Yang Y.Z., Tiwari-Pandey R., Sairam M.R. Aberrant expression of PDGF ligands and receptors in the tumor prone ovary of follitropin receptor knockout (FORKO) mouse. Carcinogenesis 2006, 27:903-915.
9. Chen X.L., Aravindakshan J., Yang Y.Z., Sairam M.R. Early alterations in ovarian surface epithelial cells and induction of ovarian epithelial tumors triggered by loss of FSH receptor. Neoplasia 2007, 9:521-531.
10. Danilovich N., Babu P.S., Xing W., Gerdes M., Krishnamurthy H., Sairam M.R. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 2000, 141:4295-4308.
11. Danilovich N., Roy I., Sairam M.R. Ovarian pathology and high incidence of sex cord tumors in follitropin receptor knockout (FORKO) mice. Endocrinology 2001, 142:3673-3684.
12. Dierich A., Sairam M.R., Monaco L., Fimia G.M., Gansmuller A., LeMeur M., Sassone-Corsi P. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13612-13617.
13. Dmitrovsky E. Tissue microarrays for hypothesis generation. J. Natl. Cancer Inst. 2004, 96:248-249.
14. Duncan T.J., Rolland P., Deen S., Scott I.V., Liu D.T., Spendlove I., Durrant L.G. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin. Cancer Res. 2007, 13:4139-4145.
15. Hata K., Nakayama K., Fujiwaki R., Katabuchi H., Okamura H., Miyazaki K. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol. Oncol. 2004, 93:215-222.
16. Janssen I., Powell L.H., Crawford S., Lasley B., Sutton-Tyrrell K. Menopause and the metabolic syndrome: the study of women's health across the nation. Arch. Intern. Med. 2008, 168:1568-1575.
17. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
18. Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 2007, 67:7095-7105.
19. Li A.J., Elmore R.G., Pavelka J.C., Karlan B.Y. Hyperandrogenemism mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol. Oncol. 2007, 107:420-423.
20. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., Thompson E.W., Quinn M.A., Rice G.E. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 2007, 120:2426-2434.
21. Marth C., Windbichler G.H., Hausmaninger H., Petru E., Estermann K., Pelzer A., Mueller-Holzner E. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 2006, 16:1522-1528.
22. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., Lewis S., Davies S., Philpott S., Lopes A., Godfrey K., Oram D., Herod J., Williamson K., Seif M.W., Scott I., Mould T., Woolas R., Murdoch J., Dobbs S., Amso N.N., Leeson S., Cruickshank D., McGuire A., Campbell S., Fallowfield L., Singh N., Dawnay A., Skates S.J., Parmar M., Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009, 10:327-340.
23. Nash M.A., Ferrandina G., Gordinier M., Loercher A., Freedman R.S. The role of cytokines in both the normal and malignant ovary. Endocr. Relat. Cancer 1999, 6:93-107.
24. Rangel L.B., Agarwal R., Sherman-Baust C.A., Mello-Coelho V., Pizer E.S., Ji H., Taub D.D., Morin P.J. Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol. Ther. 2004, 3:1021-1027.
25. Reiner A., Yekutieli D., Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003, 19:368-375.
26. Ricciardelli C., Rodgers R.J. Extracellular matrix of ovarian tumors. Semin. Reprod. Med. 2006, 24:270-282.
27. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 1998, 90:1774-1786.
28. Rossing M.A., Wicklund K.G., Cushing-Haugen K.L., Weiss N.S. Predictive value of symptoms for early detection of ovarian cancer. J. Natl. Cancer Inst. 2010, 102:222-229.
29. Rosso O., Piazza T., Bongarzone I., Rossello A., Mezzanzanica D., Canevari S., Orengo A.M., Puppo A., Ferrini S., Fabbi M. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol. Cancer Res. 2007, 12:1246-1253.
30. Slack-Davis J.K., Atkins K.A., Harrer C., Hershey E.D., Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 2009, 69:1469-1476.
31. Suganuma T., Ino K., Shibata K., Kajiyama H., Nagasaka T., Mizutani S., Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 2005, 11:2686-2694.
32. Sundfeldt K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin: an exception to the rule. Mol. Cell. Endocrinol. 2003, 202:89-96.
33. Tiwari-Pandey R., Sairam M.R. Modulation of ovarian structure and abdominal obesity in curcumin and flutamide treated aging FSH-R haploinsufficient mice. Reprod. Sci. 2009, 16:539-550.
34. Tiwari-Pandey R., Aravindakshan J., Yang Y., Sairam M.R. Normalization of hormonal imbalances, ovarian follicular dynamics and metabolic effects in follitropin receptor knockout (FORKO) mice. Mol. Human Reprod. 2007, 13:287-297.
35. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
36. Wodarz A., Näthke I. Cell polarity in development and cancer. Nat. Cell Biol. 2007, 9:1016-1024.